Skip to Main content Skip to Navigation
Journal articles

Effectiveness and Tolerance of Renin-Angiotensin System Inhibitors With Aging in Chronic Kidney Disease

C. Villain 1, 2, 3 M. Metzger 4, 5, 1 S. Liabeuf 4, 5, 6, 7, 8 A. Hamroun 1, 4, 5 S. Laville 1, 4, 5 N. Mansencal 9, 4, 5, 1 C. Combe 10, 11, 12 D. Fouque 13, 14, 15 L. Frimat 16, 17 C. Jacquelinet 1, 18, 4, 5 M. Laville 13, 14, 15 C. Ayav 19, 20 S. Briançon 19, 20 R. Pecoits-Filho 21 T. Hannedouche 22 B. Stengel 1, 4, 5 Z. A. Massy 23, 1, 4, 5 
Abstract : OBJECTIVES: Renin-angiotensin system inhibitors (RASi) are recommended for slowing chronic kidney disease (CKD) progression to kidney failure. Their effectiveness and tolerance as patients age remain uncertain because older patients have often been excluded from clinical trials. DESIGN: CKD-REIN cohort study. SETTING AND PARTICIPANTS: We studied 2762 patients with CKD stages 3 and 4 and a clinical indication for RASi enrolled between 2013 and 2016 in 40 nephrology clinics nationally representative in France. METHODS: The primary outcome was the occurrence of kidney failure or death. The secondary outcomes were the occurrence of cardiovascular events and hospitalizations with acute kidney injury (AKI) or hyperkalemia. A propensity score analysis was performed. We used Cox models to estimate hazard ratios (HRs) for each outcome associated with RASi prescription and tested interactions with age. RESULTS: Patients' mean age was 67 years, including 841 (30%) aged 75 years and older; 2178 (79%) were prescribed RASi's. During a median follow-up of 4.6 years, 33% of patients reached kidney failure or died. RASi prescription was associated with a lower risk of kidney failure or death (HR 0.79, 95% CI 0.66, 0.95), an association not modified by age (P for interaction = .72). It was not significantly associated with cardiovascular events. During the first 3 years of follow-up, 14% of patients were hospitalized with AKI or hyperkalemia, but risk was not higher among those prescribed RASi's (HR 0.75, 95% CI 0.55-1.02) and age did not modify its effect (P for interaction = .28). CONCLUSIONS AND IMPLICATIONS: This study shows that aging does not appear to modify either RASi's beneficial effects on major CKD outcomes or their potential adverse effects.
Document type :
Journal articles
Complete list of metadata
Contributor : laboratoire CarMeN Connect in order to contact the contributor
Submitted on : Thursday, February 24, 2022 - 1:24:20 PM
Last modification on : Friday, September 30, 2022 - 10:58:10 AM



C. Villain, M. Metzger, S. Liabeuf, A. Hamroun, S. Laville, et al.. Effectiveness and Tolerance of Renin-Angiotensin System Inhibitors With Aging in Chronic Kidney Disease. Journal of the American Medical Directors Association, Elsevier, 2021, S1525-8610 (21), pp.00939-7. ⟨10.1016/j.jamda.2021.10.019⟩. ⟨inserm-03587209⟩



Record views